Exact Sciences wins Wisconsin Innovation Award
MADISON, Wis.–(BUSINESS WIRE)– Exact Sciences Corp. (NASDAQ: EXAS) today announced that Cologuard was awarded a Wisconsin Innovation Award (WIA) in the “Healthcare/Health IT” category at the second annual ceremony held on August 18, 2015 at Discovery World in Milwaukee, Wisconsin. Cologuard was chosen from more than 170 entries and 33 finalists to receive one of 10 awards.
“Cologuard is an innovative test for the early detection of colon cancer that provides patients with an easy-to-use and noninvasive screening option,” said Kevin Conroy, Chairman and CEO of Exact Sciences. “The uniqueness of Cologuard is indicative of the creativity, ingenuity and collaboration taking place throughout Wisconsin. We are honored to be recognized with this award and remain committed to achieving our mission of helping eradicate colon cancer through early detection.”
Cologuard is the first and only FDA approved noninvasive stool DNA screening test for colorectal cancer. It detects the presence of cancer and precancer by analyzing both DNA and blood in the stool and offers people an easy-to-use screening test, which they can do in the privacy of their own home. Unlike other screening options, Cologuard does not require medication or dietary restrictions or bowel preparation prior to taking the test. Cologuard is available by prescription only through a healthcare provider.
Led by a steering committee of business, community and entrepreneurial leaders, the WIA hopes to encourage an even greater environment of innovation by bringing together leaders from various business sectors (e.g. tech, food, healthcare, agriculture, nonprofits, education, government) and from throughout the state of Wisconsin.
About Cologuard
Cologuard was approved by the FDA in August 2014 and results from Exact Sciences’ prospective 90-site, point-in-time, 10,000-patient pivotal trial were published in the New England Journal of Medicine in March 2014. Cologuard is included in the colorectal cancer screening guidelines of the American Cancer Society and stool DNA is listed in the screening guidelines of the U.S. Multi-Society Task Force on Colorectal Cancer.
Cologuard is indicated to screen adults of either sex, 50 years or older, who are at average risk for colorectal cancer. Cologuard is not for everyone and is not a replacement for diagnostic colonoscopy or surveillance colonoscopy in high-risk individuals. False positives and false negatives do occur. Any positive test result should be followed by a diagnostic colonoscopy. Following a negative result, patients should continue participating in a screening program at an interval and with a method appropriate for the individual patient. Cologuard performance when used for repeat testing has not been evaluated or established. For more information about Cologuard, visitwww.CologuardTest.com. Rx Only.
About Exact Sciences
Exact Sciences Corp. (NASDAQ: EXAS) is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer. The company has exclusive intellectual property protecting its noninvasive, molecular screening technology for the detection of colorectal cancer. For more information, please follow us on Twitter @ExactSciences or find us on Facebook.
